Birlasoft Ltd Q1 FY27 Earnings Call — Analysis (NSE: BSOFT)
Birlasoft reports first constant-currency growth in several quarters, with $168.7M TCV signings up 20% YoY and multiple AI-led deal wins, signalling an early momentum turnaround.
The take
Q1FY27 Revenue ₹1,379.4 Cr ( +2.3% QoQ ) . New guidance — FY27 ebitda margin at or about 15% or slightly better . New story: AI-led deal wins and capability building .
Results
Revenue ₹1,379.4 Cr (+2.3% QoQ, +7.4% YoY), EBITDA margin 16.1% (normalised), PAT ₹161 Cr, strong collections with DSO improving to 55 days and cash at ₹2,878.6 Cr.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue | ₹1,379.4 Cr | +2.3% | qoq · Q1FY27 |
| Revenue | ₹1,379.4 Cr | +7.4% | yoy · Q1FY27 |
| Constant Currency Revenue Growth (QoQ) | 0.3% | qoq · Q1FY27 · sequential quarter-on-quarter | |
| EBITDA | ₹222 Cr | +40.3% | yoy · Q1FY27 |
| EBITDA Margin | 16.1% | point_in_time · Q1FY27 · normalised, excluding Q4 one-offs | |
| PAT | ₹161 Cr | point_in_time · Q1FY27 | |
| TCV Signings | $168.7M | +20% | yoy · Q1FY27 |
| Cash and Cash Equivalents | ₹2,878.6 Cr | +9% | qoq · Q1FY27 · as of Jun-26 |
| DSO | 55 days | −improved | qoq · Q1FY27 · amongst the best in industry |
Guidance
Management guided H1 FY27 deal signings above H1 FY26, full-year signings above FY26, EBITDA margin ≥15%, ETR 29-30%, and Manufacturing/E&U recovery by Q3FY27.
What management committed to
- Birlasoft will deliver EBITDA margin at or about 15% or slightly better for the full year FY27. — at or about 15% or slightly better, FY27
- H1 FY27 deal signings (TCV) will be much better than H1 FY26 deal signings. — H1FY27
- Full-year FY27 deal signings will be better than FY26 deal signings. — FY27
- Effective tax rate for FY27 will be under 30%, in the 29%-30% range. — 29% to 30%, FY27
- Manufacturing and E&U verticals will see a momentum shift (return to sequential growth) in a quarter or two from Q1FY27. — Q3FY27
- Active client account rationalisation is complete; Birlasoft will not further reduce the active client count below the current ~200-213 range.
- Birlasoft will not pursue acquisitions for revenue aggregation; any M&A will be capability-based and strategically accretive.
- The wage hike effective 1-Jul will have only about half the gross 170-200 bps impact on Q2FY27 EBITDA margin, and the remaining impact will be recovered through productivity improvements during the year. — half the impact of 170-200 bps, Q2FY27
Key themes
AI-led deal momentum and sales investment
How the narrative shifted
- AI-led deal wins and capability building: Early investments in the Cogito AI platform, LynX, and Sigma are translating into a growing share of AI-infused deal wins, with over 25% of code now AI-generated, demonstrating a technology edge.
- Sales team expansion and domain rebalancing: Management is aggressively adding sales and domain capability headcount while trimming support roles, framing this as the key input to fix the revenue growth gap, with substantial increases expected in the next few months.
- Cautious revenue momentum after stagnation: After prolonged flat/down quarters, Q1 showed slight sequential growth, and management expects the momentum to sustain but refuses to give numeric guidance, citing market volatility.
- Margin stability with wage offset: Normalized EBITDA margin landed at 16.1% in Q1; the upcoming wage hike will partly dilute Q2 margins, but management expects to recover most through productivity, maintaining full-year margins at or above 15%.
- Vertical divergence and recovery path: BFSI and LSS verticals are driving growth, while Manufacturing and E&U (~50% of revenue) face cyclical softness; management expects both to turn around within a couple of quarters, though the timing is uncertain.
- AI-driven pricing pressure and TCV-revenue gap: Clients demand upfront productivity gains from AI, creating a disconnect between TCV bookings and recognised revenue; management calls it an industry-wide phenomenon that may take 3-4 quarters to normalise.
- Capital allocation overhang: With cash at ~₹2,879 Cr (one-third of market cap), multiple analysts pressed for a capital allocation policy; management deferred to the Board and prioritised organic growth before any acquisition, leaving the cash deployment path uncertain.
Operational commentary
- TCV signings of $168.7M, up 20% YoY, including several AI-led engagements; net new up ~$15M YoY.
- Won strategic AI partner mandate from a leading US financial services player, with renewed and expanded engagement transforming run support into an AI-first operating model.
- Secured a multiyear AI-led transformation deal for a European banking group, modernizing core applications and migrating to cloud.
- LSS vertical won Gen AI-powered engagement with a top pharma/medtech company across pharmacovigilance operations.
- Cogito AI platform demonstrated to 15+ clients; over 25% of code generated via agentic AI tools.
- Launched LynX (AI-powered test engineering) and Sigma (Agentic AIOps and AMS platform).
- Leadership team strengthened with hires for data & AI, ERP, global partnerships, and LSS vertical head.
- Sales team expansion underway, shifting headcount mix toward sales/domain and trimming support; guidance for substantial net addition in coming months.
- Active account rationalisation largely complete at ~213 clients; top 5, top 10, top 20 accounts all grew sequentially.
Analyst Q&A
Q. What specific metrics should investors track to gauge the momentum, and can you provide directional guidance on full-year order book numbers given the sales team additions?
Management stated they cannot guide specific numbers due to market volatility, but reiterated H1 signings will be much better YoY and full-year signings will exceed FY26. They emphasized pipeline health and AI-deal mix as lead indicators.
Q. How does the gap between TCV growth and revenue growth close, given deflationary pressure from AI productivity pass-through?
Angan acknowledged the pricing pressure and productivity expectations built into deals, calling it an industry phenomenon that may take 3-4 quarters to streamline, while emphasizing that renewal protection remains intact.
Q. With over one-third of market cap in cash, what is the capital allocation roadmap—buyback, acquisition, or something else?
Chandru reiterated that the Board will reward shareholders and consider capability-based M&A, but Angan stressed the priority is to deliver 3-4 quarters of organic growth before any acquisition, and that any deal will be strategic, not for revenue aggregation.
Research and educational content only. Not investment advice.